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A B S T R A C T
Objective: The anti-cancer anthracycline drug Doxorubicin (Dox) causes cardiotoxicity. We investigated the role
of protease-activated receptor 1 (PAR-1) in Dox-induced cardiotoxicity.
Methods and results: In vitro experiments revealed that PAR-1 enhanced Dox-induced mitochondrial dysfunction,
reactive oxygen species and cell death of cardiac myocytes and cardiac fibroblasts. The contribution of PAR-1 to
Dox-induced cardiotoxicity was investigated by subjecting PAR-1−/− mice and PAR-1+/+ mice to acute and
chronic exposure to Dox. Heart function was measured by echocardiography. PAR-1−/− mice exhibited sig-
nificant less cardiac injury and dysfunction compared to PAR-1+/+ mice after acute and chronic Dox admin-
istration. PAR-1−/− mice had reduced levels of nitrotyrosine, apoptosis and inflammation in their heart com-
pared to PAR-1+/+ mice. Furthermore, inhibition of PAR-1 in wild-type mice with vorapaxar significantly
reduced the acute Dox-induced cardiotoxicity.
Conclusion: Our results indicate that activation of PAR-1 contributes to Dox-induced cardiotoxicity. Inhibition of
PAR-1 may be a new approach to reduce Dox-induced cardiotoxicity in cancer patients.
1. Introduction
The anthracycline antibiotic Doxorubicin (Dox) is a very effective
anti-cancer agent that is widely used in the treatment of breast cancer,
lymphoma, leukemia, and sarcomas [1]. However, Dox induces cardi-
ovascular complications either very early after the first injection or
years after completion of chemotherapy [1]. The most common com-
plications of Dox cardiotoxicity are left ventricular dysfunction, myo-
cardial ischemia, conduction disturbances, arrhythmias, hypertension,
and venous thromboembolism. The incidence of these cardiovascular
complications can reach up to 28% of treated patients, which is de-
pendent on the dose, duration and combination with other anti-cancer
drugs [1, 2].
The major mechanism by which Dox induces heart failure involves
disruption of DNA and RNA synthesis, oxidative damage via the for-
mation of reactive oxygen species (ROS), changes in mitochondrial
membrane potential ΔΨm, apoptosis, as well as necrosis of cardiac
myocytes (CMs) [2–4]. CMs are highly susceptible to Dox because of
their high metabolic rate, their limited ability to handle oxidative stress
and their low rate of replication. Importantly, Dox-mediated injuries
are permanent. Dox-induced cardiotoxicity still occurs even with the
current anti-cancer regimes. Indeed, cardiac injury induced by cancer
therapy is a significant problem and is studied in the new field of
cardio-oncology [2, 5].
Protease-activated receptor 1 (PAR-1) is a G-protein coupled re-
ceptor that is expressed in the heart by CMs and cardiac fibroblasts
(CFs) [6–8]. In contrast to human platelets, PAR-1 is not expressed on
mouse platelets. PAR-1 activation increases vascular permeability,
leukocyte recruitment and expression of inflammatory mediators [9,
10]. We have found that PAR-1 contributes to cardiac injury. For in-
stance, we found that PAR-1−/− mice had reduced cardiac remodeling
after ischemia-reperfusion injury [6, 11, 12]. In addition, PAR-1−/−
mice had reduced perivascular fibrosis and heart failure in an angio-
tensin II infusion model [13]. Chemotherapy is often associated with
the activation of coagulation that is mediated by either an increase in
tissue factor (TF) activity on tumor cells due to increased exposure of
the negatively-charged phospholipid phosphatidylserine (TF de-en-
cryption), or the induction of TF expression within the vasculature
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with DCF or DMSO vehicle was added to the cells for 30min. Stained
cells were washed in pre-warmed FBS-free DMEM and cells incubated
with conditioned media for 60min. Then, cells were washed and stored
on ice until the final 2′, 7′–dichlorofluorescein (DCF) fluorescence
measurement. Signals were normalized with the fluorescence of DMSO
stained cells. Mitochondrial superoxide generation was analyzed by
with the MitoSOX™ Red mitochondrial superoxide indicator. Cells were
incubated with 2.5 μM MitoSOX™ for 10min at 37 °C, washed 3 times
and the fluorescence detected at 510/580 nm.
2.6. Western blot
CFs and CMs cell lysates were supplemented with 4× loading
buffer, boiled for 7min and subjected to 4–20% Mini-PROTEAN TGX
gel electrophoresis (BioRad) to separate proteins [22]. Next, proteins
were blotted onto a PVDF membrane, blocked with protein-free
blocking buffer (Thermo Fisher Scientific, Waltham, MA) and incubated
overnight at 4 °C with the primary antibodies against cleaved PARP at
Asp214 (D6X6X, 1:1000, Cell Signaling), BAX (D3R2M, 1:1000, Cell
Signaling), BCL2 (D17C4, 1:1000, Cell Signaling) or glyceraldehyde 3-
phosphate dehydrogenase (GAPDH, L-18, 1:10000, Santa Cruz Bio-
technology). Primary antibodies were visualized on washed membranes
with fluorescence labeled secondary antibodies (1:10000) for 1 h and
analyzed using an Odyssey Infrared System (LI-COR Bioscience, Lin-
coln, NE) [22]. Signal intensities were analyzed using Image J 1.43u
(National Institutes of Health, Bethesda, MD).
2.7. Acute and chronic mouse models of Dox-induced cardiotoxicity
We used male PAR-1+/+ (wild-type [WT]) and PAR-1−/− mice
(8–12 weeks old) on a C57Bl/6 J background [27]. Both mouse lines
were kept as cousin lines. Acute Dox cardiotoxicity was induced in mice
with a single intraperitoneal (i.p.) dose of Dox (20mg/kg body weight)
and cardiac function was evaluated after 5 days [4]. Chronic Dox car-
diotoxicity was induced in mice by injecting Dox (5mg/kg body
weight) weekly i.p. for 5 weeks to reach a cumulative dose of 25mg/kg
body weight after 35 days [28]. PAR-1 was inhibited by daily oral ga-
vage of WT mice with vorapaxar (SCH530348, 30 μg/kg in 20% DMSO/
80% saline solution, Axon, Reston, VA). Blood was collected from the
inferior vena cava and plasma prepared as described [29]. Tissue was
snap frozen in liquid nitrogen and stored at −80 °C [26, 30]. The study
was performed in accordance with the guidelines of the animal care and
use committee of the UNC at Chapel Hill and complies with National
Institutes of Health guidelines.
3. Echocardiography
Echocardiography was performed on conscious mice before and
after Dox treatment using a VisualSonics Vevo 2100 ultrasound system
as described [13]. Left ventricle (LV) function was measured by M-
mode echocardiography in the short-axis view at the mid-ventricular
level. The percentage of fractional shortening was assessed by mea-
suring the end-diastolic and end-systolic diameter [(end-diastolic dia-
meter–end-systolic diameter)/end-diastolic diameter× 100 (%)].
Echocardiography recording and analysis were performed in a blinded
fashion.
3.1. Statistical analysis
GraphPad Prism 5.01 (GraphPad Software Inc., La Jolla, CA) was
used for all statistical analysis. Data are represented as mean ± SEM.
For multiple-group comparison, normally distributed data were ana-
lyzed by 1- or 2-way ANOVA tests and were Bonferroni-corrected for
repeated measures over time. A P-value≤ .05 was regarded as sig-
nificant.
[14–16]. In addition, Dox increases the permeability of the en-
dothelium, which would allow access of circulating clotting factors to 
TF in the vessel wall and tissues, such as the heart [6, 17, 18]. Indeed, 
PAR-1 is the primary receptor for thrombin but can be activated by 
other proteases, such as matrix metalloproteinase (MMP) [6, 19, 20].
In this study, we investigated the role of PAR-1 in Dox-induced 
cardiotoxicity using in vitro and in vivo models.
2. Material and methods
2.1. Isolation and culture of cardiac cells
Rat CFs and CMs were isolated from one-day old rat neonates using 
a commercial kit (Worthington Biochemical Corporation, Lakewood, 
NJ) [21]. Mouse CFs and CMs were isolated from embryos (E14) from 
PAR-1+/+ and PAR-1−/− mice and cultured as described [22, 23]. 
Cells were incubated with 1 μM Dox in FBS-free media which is similar 
to the plasma concentrations in patients [24]. In addition, cells were 
stimulated with 150 μM of a PAR-1 agonist peptide (AP) or scrambled 
control peptide (Abgent, San Diego, CA) [22, 25].
2.2. Measurement of cardiac troponin-I, protein nitrotyrosine, acetylated 
p53, CXCL1 and myeloperoxidase
Cardiac and cardiac myocyte injury were quantified by measuring 
levels of cardiac troponin-I by ELISA (Life Diagnostics, West Chester, 
PA) in plasma and culture supernatant, respectively, as described [26]. 
A commercial ELISA was used to measure levels of nitrotyrosine in 
protein (Hycult, Plymouth Meeting, PA). Acetylation of p53, as marker 
for apoptosis, was measured with the PathScan® Acetylated p53 Sand-
wich ELISA Kit (Cell Signaling, Danvers, MA). CXCL1 and myeloper-
oxidase protein levels in heart lysates were analyzed using a Duo-Set® 
(R&D Systems) [25]. All assays were performed according to the 
manufacturers' instructions.
2.3. Measurement of cell viability
Cell membrane integrity was analyzed using SYTOX® Green nucleic 
acid stain. SYTOX green penetrates compromised cell membranes and 
binds to DNA. Fluorescence of DNA-bound SYTOX® Green was detected 
at 504/523 nm. Viability of cultured cells was analyzed using Alamar 
Blue® (Invitrogen, Carlsbad, CA). Cells were incubated for 2 h after 
stimulation with Alamar Blue® according to the manufacture's in-
struction and the fluorescence measured in a plate reader (SpectraMax 
M5, Molecular Devices).
2.4. Measurement of mitochondrial membrane potential ΔΨm
The fluorescent dye 5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetra-
ethylbenzimidazolocarbocyanine iodide (JC-1; R&D Systems, 
Minneapolis, MN) accumulates in mitochondria in a potential-depen-
dent manner and was employed to detect changes in mitochondrial 
membrane potential (ΔΨm) [3]. Cells were stained with JC-1 (7 μM in  
PBS) for 15 min in the dark at 37 °C, washed once and the fluorescence 
was measured at 595/525 nm with a SpectraMax M5 plate reader 
(Molecular Devices, Sunnyvale, CA). To inhibit intracellular Ca2+ sig-
naling, cells were incubated with BAPTA-AM (10 μM, Sigma-Aldrich, St. 
Louis, MO) or vehicle one hour before treatment.
2.5. Measurement of ROS
CFs and CMs were incubated with Dox and/or PAR-1 AP for in-
dicated time points. Next, cells were stained with 20 μM 2′,7′–di-
chlorofluorescin diacetate (DCFDA, Sigma-Aldrich) 90 min prior to 
analysis. For this, conditioned media was temporarily removed and 
stored in cell incubator. Pre-warmed FBS-free DMEM supplemented
4. Results
4.1. PAR-1 activation enhances Dox-induced cell injury and death of CMs
Mouse CMs from PAR-1+/+ and PAR-1−/− mice embryos (E14)
were treated with Dox (1 μM) and/or PAR-1 AP (150 μM) and cell
membrane injury and viability were analyzed. PAR-1 activation alone
did not affect cell membrane permeability for the SYTOX® Green stain
but significantly increased Dox-induced cell membrane permeability of
mouse embryonic PAR-1+/+ but not PAR-1−/− CMs (Fig. 1A). Fur-
thermore, PAR-1 activation alone had no effect on mouse CM viability
measured by AlamarBlue® but significantly increased Dox-induced cell
death of mouse CMs (Fig. 1B). Similarly, PAR-1 activation did not affect
cell viability but significantly increased Dox-induced cell death of rat
CMs measured by AlamarBlue® (Fig. 1C). In addition, PAR-1 stimula-
tion significant increased Dox-induced cardiac troponin I release from
rat CMs (Fig. 1D).
Similar to the results with mouse CMs, PAR-1 activation alone did
not affect cell membrane integrity but significantly increased Dox-in-
duced cell membrane permeability for the SYTOX® Green dye of mouse
embryonic PAR-1+/+ but not PAR-1−/− CFs (Fig. 2A). Furthermore,
PAR-1 activation alone had no effect on mouse embryonic CFs viability
but significantly increased Dox-induced reduction of cell viability of
mouse CFs analyzed by AlamarBlue® (Fig. 2B).
4.2. PAR-1 activation enhances Dox-induced mitochondrial dysfunction in
CMs
Dox has been shown to reduce ΔΨm [3, 4, 31]. Dox-induced mi-
tochondrial dysfunction is associated with increased oxidative stress
and ROS formation, including mitochondrial superoxide generation. We
measured mitochondrial function in PAR-1+/+ and PAR-1−/− em-
bryonic mouse CMs using the JC-1 staining method after incubation
with Dox (1 μM) and/or PAR-1 activation (150 μM PAR-1 AP) for 16 h
[3]. PAR-1 activation alone had no effect on the ΔΨm in mouse CMs of
both genotypes but significantly increased Dox-induced mitochondrial
dysfunction (Fig. 3A). Next, we visualized the generation of ROS using
the DCF staining method after incubating PAR-1+/+ and PAR-1−/−
embryonic mouse CMs with Dox and/or PAR-1 AP for 6 h. Again, PAR-1
activation did not affect intracellular ROS formation but increased Dox-
induced ROS generation only in PAR-1+/+ CMs (Fig. 3B). Furthermore,
PAR-1 activation resulted in an increase in mitochondria specific
Fig. 1. PAR-1 activation increases cell injury and
death of cardiac myocytes after treatment with
doxorubicin. Cardiac myocytes (CMs) were in-
cubated with 1 μM doxorubicin (Dox) and/or 150 μM
PAR-1 AP. A: Cell membrane integrity of PAR-1+/+
(white bars) and PAR-1−/− (black bars) mouse CMs
was analyzed with SYTOX® Green after 24 h stimu-
lation. B: Cell viability of PAR-1+/+ (white bars) and
PAR-1−/− (black bars) mouse CMs after 24 h sti-
mulation was determined using AlamarBlue®. C: Cell
viability of rat CMs treated with Dox and/or PAR-1
AP for 48 h was determined using AlamarBlue®. D:
Release of cardiac troponin I into the media from rat
CMs treated with Dox and/or PAR-1 AP for 48 h.
Data (mean ± SEM; n=4–9 per group) were ana-
lyzed by 2-way (A and B) and 1-way (C and D)
ANOVA. *P < .05, #P < .05 vs. control within the
same genotype, $P < .05 vs. Dox alone within the
same genotype.
Fig. 2. PAR-1 activation increases cardiac fibroblast
cell injury and death after treatment with doxor-
ubicin. Mouse cardiac fibroblasts (CFs) were in-
cubated with 1 μM doxorubicin (Dox) and/or 150 μM
PAR-1 AP. A: Cell membrane integrity of PAR-1+/+
(white bars) and PAR-1−/− (black bars) mouse CFs
was analyzed with SYTOX® Green after 24 h stimu-
lation. B: Cell viability of PAR-1+/+ (white bars) and
PAR-1−/− (black bars) mouse CFs was determined
with AlamarBlue® after 24 h stimulation. Data
(mean ± SEM; n=5–9 per group) were analyzed
by 2-way ANOVA. *P < .05, #P < .05 vs. control
within the same genotype, $P < .05 vs. Dox alone
within the same genotype.
superoxide generation in Dox-treated PAR-1+/+ CMs after 16 h
(Fig. 3C). In addition, rat neonatal CMs showed similar PAR-1 depen-
dent ΔΨm changes during Dox treatment (Fig. 3D). Again, PAR-1 AP
(150 μM) did not affect ΔΨm but significantly reduced Dox-mediated
ΔΨm changes after 16 h of stimulation (1 μM Dox) (Fig. 3D).
4.3. PAR-1 activation enhances Dox-induced mitochondrial dysfunction in
CFs
Changes in ROS and mitochondrial superoxide generation were
analyzed in PAR-1+/+ and PAR-1−/− embryonic mouse CFs 6 and 16 h
after treatment with 1 μM Dox and/or 150 μM PAR-1 AP, respectively.
Similar to mouse CMs, PAR-1 activation did not change ROS (Fig. 4A)
or superoxide (Fig. 4B) generation. However, PAR-1 activation sig-
nificantly increased Dox-induced ROS (Fig. 4A) and superoxide levels
(Fig. 4B) in PAR-1+/+ but not PAR-1−/− embryonic mouse CFs. Next,
we used rat CFs to analyze the effect of PAR-1 stimulation on ΔΨm.
Again, PAR-1 AP (150 μM) had no effect on the JC-1 ratio (Fig. 4C) but
significantly decreased Dox-induced depression of ΔΨm after 16 h of
incubation with 1 μM Dox (Fig. 4C).
PAR-1 activation induces Ca2+-dependent signaling [20]. Thus, we
pre-treated rat CFs with BAPTA (10 μM) to analyze if the observed PAR-
1 effect on ΔΨm in rat CFs after Dox incubation was Ca2+-dependent.
BAPTA and/or PAR-1 stimulation had no effect on ΔΨm (Fig. 4D).
Importantly, inhibition of Ca2+-dependent signaling abolished the
PAR-1-dependent reduction in ΔΨm in rat CFs treated with Dox and
PAR1 AP (Fig. 4D).
4.4. PAR-1 stimulation increases Dox-induced apoptosis in mouse CMs and
CFs
To analyze the effect of PAR-1 activation on Dox-induced apoptosis,
we performed Western blot analysis to detect PARP cleavage at Asp214.
PAR-1+/+ and PAR-1−/− mouse CMs (Fig. 5A) and CFs (Fig. 5B) were
incubated with Dox (1 μM) and/or PAR-1 AP (150 μM) for 24 h and
cleaved PARP protein levels were analyzed. PAR-1 activation had no
effect on PARP cleavage in CMs of both genotypes but increased Dox-
induced PARP cleavage in PAR-1+/+ but not PAR-1−/− embryonic
mouse CMs (Fig. 5A). Interestingly, PAR-1+/+ embryonic mouse CFs
showed a significant increase in PARP cleavage when stimulated with
PAR-1 AP alone compared to PAR-1−/− CFs (Fig. 5B). In addition, PAR-
1 AP further increased Dox-induced PARP cleavage in PAR-1+/+ CFs
but not PAR-1−/− embryonic mouse CFs (Fig. 5B).
4.5. Effect of PAR-1 deficiency on Dox-induced oxidative stress, markers of
apoptosis, cardiac injury and impairment of cardiac function
We used both the acute (5 days) and chronic (35 days) mouse
models of Dox-induced cardiotoxicity [4]. Dox increases cardiac injury
due to oxidative stress, inflammation, apoptotic and necrotic processes
within the heart [32, 33]. We analyzed the protein expression of the
apoptosis regulators BAX (pro-apoptotic marker) and BCL2 (anti-
apoptotic marker) before and after Dox injection in PAR-1+/+ and
PAR-1−/− mice hearts (Supplement figure). An increased in the
BAX:BCL2 ratio is associated with a more apoptotic phenotype of cells
and tissues [34]. We observed comparable BAX:BCL2 protein ratios in
both genotypes before Dox injection (Fig. 6A). Importantly, the
BAX:BCL2 protein ratio in hearts of PAR-1−/− mice was significantly
lower compared to PAR-1+/+ mice after Dox injection (Fig. 6A). An
increased apoptotic phenotype can also be determined by measuring
PARP cleavage in heart lysates. Again, we did not see any differences in
PARP cleavage at baseline (Fig. 6B). However, PARP cleavage was
higher in the hearts of Dox-treated PAR-1+/+ mice compared to PAR-
1−/− mice (Fig. 6B). Next, we assessed oxidative stress by measuring
nitrotyrosine modification of proteins in the hearts of PAR-1+/+ and
PAR-1−/− mice after Dox injection. PAR-1−/− exhibited significant
less nitrotyrosine of proteins 5 days after injection compared with PAR-
1+/+ mice (Fig. 6C). Acetylation of p53 is a marker for p53-dependent
Fig. 3. PAR-1 activation reduces mitochondrial
membrane potential ΔΨm and increases oxidative
stress in cardiac myocytes treated with doxorubicin.
Cardiac myocytes (CMs) isolated from PAR-1+/+
(white bars) and PAR-1−/− (black bars) mouse
hearts (A–C) and rat hearts (D) were incubated with
1 μM doxorubicin (Dox) and/or 150 μM PAR-1 AP. A:
Changes in the mitochondrial membrane potential
Δψm was analyzed after stimulation for 16 h using
the JC-1 staining method in mouse CMs. JC-1 595/
525 nm ratios of the respective unstimulated controls
were set to 100. B: Generation of reactive oxygen
species in mouse CMs was analyzed using the DCF
method after 6 h of Dox and/or PAR-1 AP stimula-
tion. C: Changes in mitochondrial superoxide levels
were measured in mouse CMs using the MitoSOX™
staining method. D: Mitochondrial membrane po-
tential Δψm was measured via JC-1 staining in rat
CMs after 16 h of stimulation. Data (mean ± SEM;
n=5–9 per group) were analyzed by 2-way (A–C)
and 1-way (D) ANOVA. *P < .05, #P < .05 vs.
controls of respective genotype or treatment.
$P < .05 vs. Dox alone within the same genotype.
Fig. 4. PAR-1 activation increases oxidative stress
and reduces mitochondrial membrane potential
ΔΨm and in cardiac fibroblasts treated with doxor-
ubicin. Cardiac fibroblasts (CFs) isolated from PAR-
1+/+ (white bars) and PAR-1−/− (black bars) mouse
hearts (A, B) and rat hearts (C, D) were incubated
with 1 μM doxorubicin (Dox) and/or 150 μM PAR-1
AP. A: Generation of reactive oxygen species in
mouse CFs was analyzed using the DCF method after
6 h of Dox and/or PAR-1 AP stimulation. B: Changes
in mitochondrial superoxide levels were measured in
mouse CFs using the MitoSOX™ staining method. C:
Mitochondrial membrane potential Δψm was mea-
sured via JC-1 staining in rat CFs after 16 h of sti-
mulation. D: Changes in the JC-1 ratio in rat CFs with
the Ca2+ chelator (BAPTA, 10 μM, gray bars) or ve-
hicle control (white bars) after incubation with 1 μM
Dox (Dox) and/or 150 μM PAR-1 AP for 16 h. Data
(mean ± SEM; n=5–9 per group) were analyzed
by 2-way (A, B, D) and 1-way (C) ANOVA. *P < .05,
#P < .05 vs. controls of respective genotype or
treatment. $P < .05 vs. Dox alone within the same
genotype.
Fig. 5. PAR-1 activation increases apoptosis in cardiac myocytes and cardiac fibroblasts treated with doxorubicin. Mouse cardiac myocytes (CMs) and cardiac
fibroblasts (CFs) from PAR-1+/+ (white bars) and PAR-1−/− (black bars) mouse hearts were stimulated with 1 μM Doxorubicin (Dox) and/or 150 μM PAR-1 AP for
24 h. Quantifications and representative Western blots of PARP cleavage at Asp214 (89 kDa fragment) of CMs (A) and CFs (B). Cleaved PARP levels of the Dox alone
group in PAR-1+/+ were set to 100. GAPDH (39 kDa) protein levels were used as loading control. Data (mean ± SEM; n=3–6 per proup) were analyzed by 2-way
ANOVA. *P < .05, #P < .05 vs. controls. $P < .05 vs. Dox alone within the same genotype.
apoptosis and was increased 5 days after Dox injection in both geno-
types. However, we observed significantly less p53 acetylation in PAR-
1−/− mice compared to PAR-1+/+ mice (Fig. 6D). In addition, we
measured markers of inflammation, CXCL1 and myeloperoxidase, be-
fore and 5 days after Dox injection. Dox injection resulted in increased
CXCL1 protein levels in the heart of both genotypes (Fig. 6E). However,
PAR-1+/+ hearts exhibited much higher levels of CXCL1 after Dox in-
jection compared to PAR-1−/− hearts (Fig. 6E). Furthermore, only
PAR-1+/+ hearts exhibited increased levels of myeloperoxidase after
Dox injection which was higher compared to PAR-1−/− mice hearts
(Fig. 6F).
Importantly, PAR-1−/− mice exhibited significantly less cardiac
injury in the acute model of Dox-induced cardiotoxicity (Fig. 7A).
Furthermore, PAR-1−/− mice had less impairment of cardiac function
after Dox administration in both the acute and chronic models com-
pared with PAR-1+/+ mice (Fig. 7B and C, Supplement table 1 and
Supplement table 2).
4.6. Effect of inhibition of PAR-1 in WT mice treated with Dox
We determined if PAR-1 inhibition in WT mice with vorapaxar was
also protective against Dox-induced cardiotoxicity. PAR-1+/+ and PAR-
1−/− mice were orally gavaged with vorapaxar (30 μg/kg) or vehicle
control 1 h before and then daily after Dox injection. Importantly,
vorapaxar reduced Dox-induced cardiac impairment of WT mice
(Fig. 7D, Supplement table 3). As expected, PAR-1−/− mice had less
impairment of cardiac function after Dox treatment compared to WT
mice and this was not affected by administration of vorapaxar (Fig. 7D,
Supplement Table 3).
5. Discussion
In this study, we identified a pathogenic role of PAR-1 in Dox-in-
duced cardiotoxicity. In vitro experiments revealed that PAR-1 activa-
tion enhances Dox-mediated mitochondrial dysfunction in rat and
mouse CFs and CMs. The PAR-1-dependent increase in Dox-induced
mitochondrial dysfunction was associated with increased ROS and mi-
tochondrial superoxide formation, and apoptosis of CFs and CMs.
Consistent with our data, PAR-1 has been shown to activate p53 and
increase apoptosis of lung epithelial cells treated with leukocyte elas-
tase [35]. In vivo, we observed an increased BAX:BCL2 protein ratio,
PARP cleavage, oxidative stress, and activation of the p53 pathway, as
well as increased inflammation in the hearts of PAR-1+/+ compared to
PAR-1−/− mice after Dox injection. Importantly, PAR-1−/− mice were
protected from cardiotoxicity in both acute and chronic Dox-induced
heart failure models. In addition, the PAR-1 inhibitor vorapaxar
Fig. 6. PAR-1 deficiency is associated with reduced
oxidative stress, apoptosis and inflammation in the
heart after doxorubicin injection. Heart samples were
collected from PAR-1+/+ (white bar) and PAR-1−/−
(black bar) mice before, 2 and 5 days after doxor-
ubicin (Dox, 20mg/kg) injection. A: BAX:BCL2 pro-
tein ratio and B: Levels of cleaved PARP in the hearts
before and 2 days after Dox injection. C: Levels of
nitrotyrosine, D: Levels of acetylated p53 acetylation,
E: Levels of CXCL1 and F: myeloperoxidase in the
hearts before and 5 days after Dox injection. Data
(mean ± SEM; n=5–9 per group) were analyzed
by 2-way ANOVA. *P < .05, #P < .05 vs. day 0
within the same genotype.
reduced Dox-induced cardiotoxicity in WT mice.
We showed that PAR-1 activation contributes to cardiac remodeling
and cardiac dysfunction after cardiac injury induced by ischemia-re-
perfusion injury, as well as treatment with isoproterenol or angiotensin
II infusion [11, 13, 21]. In addition, we found that PAR-1 signaling
contributes to angiotensin II-induced cardiovascular remodeling and
inflammation [13]. Interestingly, inhibition of the angiotensin receptor
reduced Dox toxicity in rats and humans, which may be due, in part, to
reduced PAR-1 activation [2, 36].
A major finding of our study is that PAR-1 activation enhances Dox-
mediated mitochondrial dysfunction and this increases mitochondrial
superoxide, ROS and cardiac cell death. In line with our observation, a
study showed that PAR-1 stimulation of platelets leads to a loss of ΔΨm
due to increased intracellular H2O2 generation [37]. Importantly, Dox-
induced apoptosis is linked to Ca2+-dependent ROS formation, mi-
tochondrial dysfunction and apoptosis [38, 39]. Here, we showed that
Ca2+ signaling inhibition abolished the effect of PAR-1 activation on
Dox-induced changes in ΔΨm reduction in rat CFs. This suggests that
PAR-1 activation enhances pathologic Dox-mediated Ca2+ signaling
enhancing the toxic feedback cycle of ROS generation and mitochon-
dria injury leading to cell death. Our data are in line with a recent
publication, using Q94, an antagonist of PAR-1-dependent Ca2+ sig-
naling, in Dox-induced kidney injury [40]. There, the authors linked
PAR-1 activation to enhanced Ca2+-dependent oxidative stress and
apoptosis in podocytes after treatment with Dox [40].
PAR-1 was shown to enhance the progression of cancer in several
models, including breast, colon, prostate, and melanoma [41]. The
thrombin–PAR-1 pathway promotes invasion of tumor cells by in-
creasing the secretion of MMPs [42]. Further, PAR-1 can stimulate
melanoma cell chemokinesis and metastasis and correlated with the
metastatic potential of melanoma cells [43, 44]. Silencing of PAR-1 in
these cells reduced tumor growth and metastasis in vivo [45]. In ad-
dition, inhibition of thrombin-induced PAR-1 activation by dabigatran
etexilate reduced proliferation, migration, and pro-angiogenetic effects
of breast and glioblastoma cancer cell lines in vitro and in vivo [46, 47].
Co-treatment with both low dose cyclophosphamide and dabigatran
etexilate also led to significantly smaller mammary tumors and fewer
lung metastases than mice treated with cyclophosphamide or dabiga-
tran etexilate alone [48].
PAR-1 is the major thrombin receptor on human platelets. Cancer is
associated with increased platelet activation [49]. Activated platelets
release extracellular vesicles and growth factors that can contribute to
tumor proliferation, growth, invasion, and angiogenesis [49]. Interest-
ingly, a PAR-1 polymorphism with increased PAR-1 expression/re-
activity was associated with increased tumor progression, relapse and
mortality [50]. The effect of PAR-1 inhibition by the FDA-approved
PAR-1 inhibitor vorapaxar has not yet been evaluated in cancer pa-
tients. However, long-term antiplatelet treatments in the TRITON,
TRACER, PEGASUS, DAPT and the APPRAISE-2 trial were linked to an
increase of first occurrence of solid cancers in patients with myocardial
infarctions. [51] A possible explanation is that “cancer follows
bleeding” or more accurately persistent platelet inhibition and/or an-
ticoagulation promoted development and dissemination of early-stage
unclassified cancer cells [51]. However, the survival rate of trial pa-
tients with newly occurred cancer did not differ compared to a control
cohort [51].
Most importantly, we were able to show that vorapaxar treatment of
mice improved the heart function to levels seen in PAR-1−/− mice after
Dox injection. This suggests that vorapaxar could reduce the cardiotoxic
effects of Dox in patients. We did not see any off-target effects of vor-
apaxar since it had no additional effect in PAR-1−/− mice with regards
to the heart function. Our data are highly relevant for the field of
cardio-oncology. We found a new therapeutic indication of an already
FDA-approved drug which will shorten the time to clinic significantly to
improve cancer patients' life.
In conclusion, our study showed that interference with the PAR-1
signaling pathway reduced Dox cardiotoxicity in mice. Dox use is lim-
ited due to its cardiotoxicity. Reducing the cardiotoxic effects of che-
motherapeutic drugs is an emerging topic in cardio-oncology.
Inhibition of pathologic PAR-1 signaling during chemotherapy might be
a potential way to improve chemotherapy outcome. Importantly, the
beneficial effects of PAR-1 inhibition may extend to the tumor itself.
Our data suggest that the PAR-1 inhibitor vorapaxar might be beneficial
not only by reducing cardiotoxicity by also by preventing thrombotic
Fig. 7. PAR-1 deficiency and PAR-1 inhibition is
associated with reduced cardiac injury and reduced
heart failure induced by doxorubicin. A: Cardiac in-
jury was assessed by measuring levels of cardiac
troponin I in the plasma from PAR-1+/+ (white bar)
and PAR-1−/− (black bar) mice at different times
after doxorubicin (Dox, 20mg/kg) injection. B:
Echocardiographic analysis of heart function shown
as fractional shortening of PAR-1+/+ (white bar)
and PAR-1−/− (black bar) mice before and 5 days
after Dox (20mg/kg) injection. C: Fractional short-
ening of mice before and after injection of Dox
weekly (5mg/kg) for 35 days (cumulative dose
25mg/kg). D: PAR-1+/+ and PAR-1−/− mice were
treated before and daily after doxorubicin (Dox) in-
jection (20mg/kg) with vehicle (white bars) or the
PAR-1 inhibitor vorapaxar (30 μg/kg, gray bar) by
oral gavage. Heart function was measured by echo-
cardiography and shown as fractional shortening at
day 5. Data (mean ± SEM; n=5–9 per group [A-C]
and for D: PAR-1+/+n=10–12 and PAR-1−/
−n=4–5) were analyzed by 2-way ANOVA.
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certain malignant tumors themselves.
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